Balyasny Asset Management L.P. Takes $4.95 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)

Balyasny Asset Management L.P. purchased a new stake in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 301,152 shares of the company's stock, valued at approximately $4,951,000. Balyasny Asset Management L.P. owned approximately 0.56% of Upstream Bio at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. Moody Aldrich Partners LLC acquired a new stake in shares of Upstream Bio during the 4th quarter worth approximately $1,229,000. Legal & General Group Plc bought a new stake in Upstream Bio in the 4th quarter valued at about $28,000. Barclays PLC bought a new stake in Upstream Bio in the 4th quarter valued at about $445,000. Corebridge Financial Inc. bought a new stake in Upstream Bio in the 4th quarter valued at about $142,000. Finally, Invesco Ltd. bought a new stake in shares of Upstream Bio during the fourth quarter valued at about $256,000.

Upstream Bio Stock Up 2.7%

Shares of NASDAQ UPB traded up $0.24 during midday trading on Friday, hitting $9.02. 117,086 shares of the company's stock were exchanged, compared to its average volume of 325,325. Upstream Bio, Inc. has a 12-month low of $5.14 and a 12-month high of $29.46. The business's fifty day moving average price is $8.06 and its two-hundred day moving average price is $13.14.

Upstream Bio (NASDAQ:UPB - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The firm had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million. Sell-side analysts expect that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.